SYNTHESIS, SPECTRAL AND MOLECULAR CHARACTERIZATION OF SOME NOVEL 2, 5-DISUBSTITUTED-1, 3, 4–OXADIAZOLE DERIVATIVES AND EVALUATION OF IN VIVO ANTITUMOUR ACTIVITY AGAINST HT 29 CELL LINE
Abstract
Neoplasia is a type of abnormal and excessive growth of tissue. The growth of a neoplasia is uncoordinated with that of the normal surrounding tissue, and it persists growing abnormally, even if the original trigger is removed. This abnormal growth usually forms a mass. The main objective of the present research work was the synthesis, characterization and evaluation of in vivo antitumour activity of some novel 2, 5-disubstituted 1, 3, 4-oxadiazole derivatives. The in vivo antitumour activity of synthesized compounds was evaluated by HT 29 cell line induced malignant ascites on mouse model. The apoptosis of HT 29 cells was evaluated by using Gimsa and H33342 stain and the apoptosis ratios were analysed by FCM using AnnexinV-FITC/PI staining. The present experimental data displayed that the mortality was less in all groups except in tumour control group and all the synthesized compounds AB1-AB8 (100 mg/kg) significantly increased the PILS. While 5-FU increased the life span of 97.72%, and the PILS of synthesized compounds were found to be 45.45%, 59.09%, 68.18%, 56.81%, 38.63%, 84.09%, 77.27% and 90.90%. So the Synthesized compounds AB1-AB8 at the dose of 100 mg/kg significantly improved the overall survival of all treated animals and 5-FU was not significantly differed from each other in improving the overall survival of HT-29 cells. The apoptosis ratios of synthesized compounds were found as followed: AB1=26%; AB2=37.6%; AB3=43%; AB4=29%; AB5=24.1%; AB6=59.2%; AB7=48.2%; and AB8=63% respectively, while that of the Group-II (T. control) was 6.1%. When compared with standard drug 5-FU: 66.2%, it was indicated that compound AB8>AB6>AB7>AB3 were able to significantly induce HT-29 cells apoptosis.
Keywords:
Neoplasia, antitumour, malignant ascites, HT 29, apoptosis, PILSDOI
https://doi.org/10.25004/IJPSDR.2018.100602References
Gupta RR, Kumar M, Gupta V. Heterocyclic Chemistry. Volume II: Five membered Heterocycles India, 1st Edn, Springer, 2005, pp. 525-546.
Hetzheim A, Möckel K. Recent advances in 1, 3, 4-oxadiazole chemistry. Adv. Heterocycl. Chem. 1967; 7: 183-224.
Kharb R, Sharma PC, Bhandari A, Yar MS. Synthesis, spectral characterization and anthelmintic evaluation of some novel imidazole bearing triazole derivatives. Der Pharmacia Lettre 2012; 4(2): 652-657.
Santagati M, Modica M, Santagati A, Russo F, Caruso A, Cutuli V, Di Pietro E, Amico-Roxas M. Synthesis and pharmacological properties of benzothiazole,1,3,4-oxadiazole and 1,3,4-thiadiazole derivatives. Pharmazie. 1994; 49(12): 880-884.
Li Y, Liu J, Zhang H, Yang X, Liu Z. Stereoselective synthesis and fungicidal activities of (E)-alpha-(methoxyimino)-benzeneacetate derivatives containing 1,3,4-oxadiazole ring. Bioorganic & Medicinal Chemistry Letters. 2006; 16(8):2278-2282.
Kucukguzel SG, Oruc EE, Rollas S, Sahin F, Ozbek A. Synthesis, characterisation and biological activity of novel 4-thiazolidinones, 1,3,4-oxadiazoles and some related compounds. Eur. J. Med. Chem. 2002; 37(3): 197-206.
Ilango K, Valentina P, Umarani N, Kumar T. Synthesis and characterization of 2,5-disubstituted-1,3,4-oxadiazoles as potential inflammatory agents. J Young Pharm. 2009; 1(1):72-76.
Jakubkiene V, Burbuliene MM, Mekuskiene G, Udrenaite E, Gaidelis P, Vainilavicius P. Synthesis and anti-inflammatory activity of 5-(6-methyl-2-substituted 4-pyrimidinyloxymethyl)-1,3,4-oxadiazole-2-thiones and their 3-morpholinomethyl derivatives. Farmaco. 2003; 58:323-328.
OECD Guidelines for the Testing of Chemicals, Volume 1, Number 4, September 2006, pp. 1-14(14).
Boik J. Natural Compounds in Cancer Therapy. Oregon Medical Press, Minnesota, USA, 2001, pp. 25.
Thummar VR, Parasuraman S, Basu D, Raveendrana R. Evaluation of in vivo antitumor activity of cleistanthin B in Swiss albino mice. J Tradit Complement Med. 2016 Oct; 6(4): 383–388.
Raihan MO, Tareq SM, Brishti A, Alam MK, Haque A, Ali MS. Evaluation of antitumor activity of Leea indica (Burm.f.) Merr. Extract against Ehrlich ascites carcinoma (EAC) bearing Mice. Am J Biomed Sci. 2012; 4(2):143–152.
Chih HW, Chiu HF, Tang KS, Chang FR, Wu YC. Bullatacin a potent antitumor annonaceous acetogenin, inhibits proliferation of human by apoptosis induction. Life Sci. 2001; 69(11):1321-1331.
Lallemand B, Gelbcke M, Dubois J, Prévost M, Jabin I, Kiss R. Structure–activity relationship analyses of glycyrrhetinic acid derivatives as anticancer agents. Mini Rev Med Chem. 2011; 11(10):881–887.
Wang P, She G, Yang Y, Li Q, Zhang H, Liu J, Cao Y, Xu X, Lei H. Synthesis and biological evaluation of new ligustrazine derivatives as antitumour agents. Molecules 2012; 17(5):4972-4985.
Gupta SK, editor. Drug Screening Methods (Preclinical evaluation of New Drugs) 2nd ed. New Delhi: Jaypee Brothers Medical Publishers, 2010, pp. 214.
Published
Abstract Display: 417 
PDF Downloads: 517 
